Wockhardt Limited (WOCKPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹306B
Strengths
Risks
Fair value as of: Aug 25, 2026
From 21 valuation models · updated today
Share price +2.7% over the past month.
Below-average quality, and trading another 844% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹229.95). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.
How to read this chart
60‑month range ₹149.60 – ₹2,152 · fair‑value band ₹152.47 – ₹229.95 · the ₹1,900 price screens above the ₹201.10 fair value. Dashed = 300-day average. As of Aug 25, 2026.
Analysis
Wockhardt Limited (WOCKPHARMA) currently trades at ₹1,900, while our model-based Fair Value estimate is ₹201.10, implying the stock looks roughly 89.4% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Wockhardt Limited generated revenue of ₹36.5B at a net margin of 11.2%. Revenue grew 25.9% year over year. It earns a return on equity of 4.0%. Net debt stands at ₹19.1B. Fundamentals as of Aug 25, 2026
Our scenario range runs from ₹152.47 (bear case) to ₹229.95 (bull case); at ₹1,900, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 75% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at -89%, WOCKPHARMA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 21 models by family
Widest divergence: Multiples (₹242.35) versus Dividend Discount (₹1.44). Highest evidence: Residual Income (76).
Notify me when WOCKPHARMA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally.
Full company description
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Wockhardt Limited reported revenue of ₹33.2B in FY2026 versus ₹32.1B in FY2022, a compound +0.8%/yr. Reported net income was ₹2.1B in FY2026.
WOCKPHARMA screens 89% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.00 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $17.41 | $11.29 | -35% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $36.74 | $15.37 | -58% |
| Sandoz Group SDZ | CHF 72.64 | CHF 48.68 | -33% |
| Zoetis Inc ZTS | $73.54 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Wockhardt Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Wockhardt Limited (WOCKPHARMA) overvalued or undervalued?
What is the fair value of WOCKPHARMA?
What is the quality score of WOCKPHARMA?
What is the revenue of Wockhardt Limited (WOCKPHARMA)?
What is the net profit margin of WOCKPHARMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wockhardt Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.